Salim S. Abdool Karim, MD, PhD, is a South African clinical infectious diseases epidemiologist who is widely recognised for his research contributions in HIV prevention and treatment. He is Director of the CAPRISA, President of the South African Medical Research Council, and Pro Vice-Chancellor (Research) at the University of KwaZulu-Natal in Durban, South Africa. He is also Professor of Clinical Epidemiology at the Mailman School of Public Health at Columbia University, Adjunct Professor of Medicine at Weill Medical College of Cornell University and Associate Member of The Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University. His contributions to microbicides for HIV prevention spans two decades and culminated in the CAPRISA 004 tenofovir gel trial which provided proof-of-concept that antiretroviral drugs can prevent sexually transmitted HIV infection and HSV-2 in women. He is co-inventor on patents which have been used in several HIV vaccine candidates and his clinical research on TB-HIV treatment has shaped international guidelines on the clinical management of co-infected patients. He is Chair of the UNAIDS Scientific Expert Panel and an elected Fellow of the African Academy of Sciences, the World Academy of Sciences, the Academy of Science in South Africa, the Royal Society of Science in South Africa and he is a Foreign Associate Member of the Institute of Medicine. View Faculty CV here (PDF).